Compare APGE & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APGE | FHI |
|---|---|---|
| Founded | 2022 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.0B |
| IPO Year | 2023 | N/A |
| Metric | APGE | FHI |
|---|---|---|
| Price | $77.22 | $51.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $100.00 | $49.00 |
| AVG Volume (30 Days) | ★ 818.6K | 609.6K |
| Earning Date | 11-10-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.61% |
| EPS Growth | N/A | ★ 50.93 |
| EPS | N/A | ★ 4.77 |
| Revenue | N/A | ★ $1,742,513,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | N/A | $6.95 |
| P/E Ratio | ★ N/A | $10.93 |
| Revenue Growth | N/A | ★ 8.98 |
| 52 Week Low | $26.20 | $35.05 |
| 52 Week High | $78.12 | $54.42 |
| Indicator | APGE | FHI |
|---|---|---|
| Relative Strength Index (RSI) | 73.47 | 61.18 |
| Support Level | $74.48 | $50.01 |
| Resistance Level | $76.87 | $52.89 |
| Average True Range (ATR) | 3.37 | 0.96 |
| MACD | -0.06 | 0.29 |
| Stochastic Oscillator | 91.13 | 74.75 |
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $843.7 billion in managed assets at the end of June 2025, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (2%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 52% of Federated's revenue this year, compared with 29%, 11%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).